Zacks Research downgraded Rezolute Inc. from hold to strong sell on Saturday, July 18. This rating cut signals strong bearish sentiment for the clinical-stage biopharmaceutical company.
Rezolute develops metabolic disease therapies, including RZ358 for congenital hyperinsulinism. The company is also developing RZ402 for diabetic macular edema.
The downgrade follows a period of stock volatility. Analysts cite concerns regarding clinical trial data and the competitive landscape. The company's financial position is also a potential driver for the rating change.